Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STI 6129

Next Previous
X
Search
Drug Profile

STI 6129

Alternative Names: CD38 ADC - Sorrento Therapeutics; LNDS-1001; STI-6129

Latest Information Update: 28 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sorrento Therapeutics
  • Developer Sorrento Therapeutics; Zhejiang ACEA Pharmaceutical
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Oesophageal cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • No development reported Amyloid light-chain amyloidosis

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for phase-I development in Amyloid-light-chain-amyloidosis in USA (IV, Infusion)
  • 28 Apr 2023 Sorrento Therapeutics withdraws a phase I trial for Amyloid light-chain amyloidosis due to chapter 11 bankruptcy filled by the company (NCT05692908)
  • 08 Feb 2023 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT05565807)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top